fb2001
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
2
Phase 4
0
Earliest trial started Mar 26, 2021 (NCT04766931)
Timeline
Indications
Mechanism of action
- Replicase polyprotein 1aINHIBITOR
Replicase polyprotein 1a inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05675072 | Phase 2/Phase 3 (Phase 3) | Jan 4, 2023 | Frontier Biotechnologies Co., Ltd. |
| NCT05583812 | Phase 1 | Oct 21, 2022 | Frontier Biotechnologies Co., Ltd. |
| NCT05445934 | Phase 2/Phase 3 (Phase 3) | Jul 5, 2022 | Frontier Biotechnologies Co., Ltd. |
| NCT05415241 | Phase 1/Phase 2 (Phase 2) | Jun 9, 2022 | Frontier Biotechnologies Co., Ltd., Government of China, Jiao Tong University |
| NCT05197179 | Phase 1 | Dec 29, 2021 | Frontier Biotechnologies Co., Ltd., Jiao Tong University |
| NCT04766931 | Phase 1 | Mar 26, 2021 | Frontier Biotechnologies Co., Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Frontier Biotechnologies Co., Ltd. | For profit | 6 | 5 | 3 | 2021 |
| Jiao Tong University | Academic/Hospital | 2 | 1 | 2 | 2021 |
| Government of China | Government | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1